Patents matching “treatment”

US 10617723

C. novyi for the treatment of solid tumors in humans

Biomed Valley Discoveries, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

US 10617674

Dosage regimen for the treatment of acute exacerbations of inflammatory conditions

MEREO BIOPHARMA 1 LIMITED · Granted Apr 14, 2020 · Expires Apr 9, 2040

US 10618938

Compositions for colon cleansing and the treatment of gastrointestinal disorders

IRONWOOD PHARMACEUTICALS, INC. · Granted Apr 14, 2020 · Expires Apr 9, 2040

US 10619157

Cancer treatment

Ionis Pharmaceuticals, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

US 10617709

miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers

The Board of Regents of the University of Texas System · Granted Apr 14, 2020 · Expires Apr 9, 2040

US 10614684

Treatment of kidney diseases associated with elevated AVP

THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE · Granted Apr 7, 2020 · Expires Apr 2, 2040

US 10610535

Diarylpropionitrile therapy for treatment of multiple sclerosis

The Regents of the University of California · Granted Apr 7, 2020 · Expires Apr 2, 2040

US 10610510

Treatment of circadian rhythm disorders

VANDA PHARMACEUTICALS INC. · Granted Apr 7, 2020 · Expires Apr 2, 2040

US 10610563

Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2

BIOXCEL CORPORATION · Granted Apr 7, 2020 · Expires Apr 2, 2040

US 10610511

Method of treatment

VANDA PHARMACEUTICALS INC. · Granted Apr 7, 2020 · Expires Apr 2, 2040

US 10611998

Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

The Regents of the University of California · Granted Apr 7, 2020 · Expires Apr 2, 2040

US 10612025

Antisense oligonucleotides for the treatment of eye disease

ProQR Therapeutics II B.V. · Granted Apr 7, 2020 · Expires Apr 2, 2040

US 10603306

Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease

MEREO BIOPHARMA 1 LIMITED · Granted Mar 31, 2020 · Expires Mar 26, 2040

US 10603363

Treatment of retinitis pigmentosa using engineered meganucleases

Precision BioSciences, Inc. · Granted Mar 31, 2020 · Expires Mar 26, 2040

US 10604807

Methods for diagnosing and assessing treatment for Cushing's syndrome

Corcept Therapeutics Incorporated · Granted Mar 31, 2020 · Expires Mar 26, 2040

US 10604493

Compositions, methods of use, and methods of treatment

The Regents of the University of California · Granted Mar 31, 2020 · Expires Mar 26, 2040

US 10603356

Compositions and method for treatment of inflammatory bowel disease

The Regents of the University of California · Granted Mar 31, 2020 · Expires Mar 26, 2040

US 10603308

Methods and compositions for treatment of epileptic disorders

OVID THERAPEUTICS INC. · Granted Mar 31, 2020 · Expires Mar 26, 2040

US 10603296

Compositions and methods for diagnosis and treatment of neuromuscular disorders

United States of America as represented by the Secretary of the Air Force · Granted Mar 31, 2020 · Expires Mar 26, 2040

US 10597732

Allogeneic autophagosome-enriched composition for the treatment of disease

Providence Health & Services—Oregon · Granted Mar 24, 2020 · Expires Mar 19, 2040

US 10597731

Allogeneic autophagosome-enriched composition for the treatment of disease

Providence Health & Services—Oregon · Granted Mar 24, 2020 · Expires Mar 19, 2040

US 10596216

Use of a Withania extract for the treatment of amyloid-related diseases

Ethnodyne and Centre National de la Recherche Scientifique (CNRS) · Granted Mar 24, 2020 · Expires Mar 19, 2040

US 10588874

Toxic aldehyde related diseases and treatment

Aldeyra Therapeutics, Inc. · Granted Mar 17, 2020 · Expires Mar 12, 2040

US 10588984

Virus-like particle conjugates for diagnosis and treatment of tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 17, 2020 · Expires Mar 12, 2040